Antengene - Model XPOVIO - Diffuse Large B-Cell Lymphoma (DLBCL) Selinexor
Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over 40% in most Asian countries.
Products Details
The most common symptom of DLBCL is painless and progressive swelling of lymph nodes. Around 30% of patients with DLBCL experience B symptoms (fever, weight loss, and night sweats). Approximately 40% of DLBCLs originate from extranodal sites, and the most common extranodal sites are the gastrointestinal tract and bone marrow. 3
Currently, patients with DLBCL can achieve total remission after the first-line treatment with the R-CHOP regimen, with the other 40%-50% eventually relapsing or becoming refractory. Among those patients with relapsed/refractory DLBCL, approximately 10% can recover after standard salvage therapies and autologous hematopoietic stem cell transplantation, while the other 90% still face a poor prognosis. 4
Customer reviews
No reviews were found for Antengene - Model XPOVIO - Diffuse Large B-Cell Lymphoma (DLBCL) Selinexor. Be the first to review!